Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72721 record(s)

Req # A-2024-000380

Adverse Drug Reactions (ADRs). Report numbers: 001082646, 001083506, 001085717, E2B_07075185, 001084039, E2B_07033111, E2B_06787144, E2B_02939494, E2B_06001457, E2B_05383440.

Organization: Health Canada

589 page(s)
September 2024

Req # A-2024-000387

Adverse Drug Reactions (ADRs). Report numbers: 1063643, 1079966, E2B_07049389, 001086469.

Organization: Health Canada

117 page(s)
September 2024

Req # A-2024-000394

Adverse Drug Reactions (ADRs). Report numbers: E2B_07076272, E2B_07087654, 001082645, 001085334, E2B_07085288, 001082803, 001085543.

Organization: Health Canada

1976 page(s)
September 2024

Req # A-2024-000396

Adverse Drug Reactions (ADRs) for LEUPRORELIN. Report numbers: E2B_06403578, E2B_06407900, E2B_06419779, E2B_06423889, E2B_06459016, E2B_06463299, E2B_06463345, E2B_06475485, E2B_06478517, E2B_06487641.

Organization: Health Canada

89 page(s)
September 2024

Req # A-2024-000397

Adverse Drug Reactions (ADRs) for LEUPRORELIN. Report numbers: E2B_06496955, E2B_06506828, E2B_06509952, E2B_06529216, E2B_06544347, E2B_06565555, E2B_06571302, E2B_06582856, E2B_06586379, E2B_06589250.

Organization: Health Canada

77 page(s)
September 2024

Req # A-2024-000399

Adverse Drug Reactions (ADRs) for LEUPRORELIN. Report numbers: E2B_06590322, E2B_06612354, E2B_06616541, E2B_06651704, E2B_06656709, E2B_06671326, E2B_06674052, E2B_06676787, E2B_06683023, E2B_06687133.

Organization: Health Canada

95 page(s)
September 2024

Req # A-2024-000400

Adverse Drug Reactions (ADRs) for LEUPRORELIN. Report numbers: E2B_06698587, E2B_06700717, E2B_06700910, E2B_06713399, E2B_06718480, E2B_06721498, E2B_06732015, E2B_06732708, E2B_06733896, E2B_06746417.

Organization: Health Canada

71 page(s)
September 2024

Req # A-2024-000414

Adverse Drug Reactions (ADRs). Report numbers: E2B_07080689, E2B_07080686.

Organization: Health Canada

25 page(s)
September 2024

Req # A-2024-000415

Adverse Drug Reaction (ADR). Report number: E2B_07005446.

Organization: Health Canada

10 page(s)
September 2024

Req # A-2024-000432

Adverse Drug Reaction (ADR). Report number: E2B_07116717.

Organization: Health Canada

116 page(s)
September 2024
Date modified: